Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases

NCT02580539 is registered in ClinicalTrials.gov with Dr. Jean-Sebastien Delisle, MD, PhD as lead sponsor.

NCT NCT02580539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02580539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases
Lead sponsor
Dr. Jean-Sebastien Delisle, MD, PhD
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2015
Completion date
May 31, 2025
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus infections, lymphoma, post-transplant lymphoproliferative disorder